FOR PRACTIONERS
The EndoSure Test* is a game changer. It is the only Non-Invasive, 30-Minute,¹ Objective Clinical Decision Support Tool facilitating a Highly-Accurate Diagnosis of Endometriosis
The test can be performed during the initial encounter for patients presenting with pelvic or menstrual pain as well as other abdominal symptoms.
The EndoSure Test*
The test is easy to perform, and provides simple, objective and definitive data in 30 minutes to support the diagnosis of endometriosis, regardless of the stage of disease.
Equally, compelling is how the EndoSure Test* is suitable for post-treatment patient monitoring as well as routine screening.
Download our Brochure
During the Electrogastrogram (EGG)/Electroviscerogram (EVG) portion of the test, the proprietary TRICORDER-3L collects data on myoelectrical activity from the patient’s gastrointestinal tract. Research has shown that the neurotransmitters secreted by endometriosis tissue uncouple normal myoelectrical control in the gastrointestinal tract, resulting in idiosyncratic abnormally high frequency activity, producing a unique myoelectric signal.² Calculations, based on published research,³ are conducted by the EndoSure support software using this EGG/EVG data. The resulting information can be used to support the diagnosis of endometriosis.
About Us
EndoSure offers the only non-invasive, 30-minute test to support the diagnosis of endometriosis that not only fills the gap, but addresses the vacuum in this area of women’s health care.*
© July 2024 ENDOSURE, Inc. All rights reserved
1. Approximately 15-20 minutes of patient preparation time may be required prior to performing the test.
2. Mathias JR, Franklin R, Quast DC, Fraga N, Loftin CA, Yates L, Harrison V. Relation of endometriosis and neuromuscular disease of the gastrointestinal tract: new insights. Fertil Steril. 1998 Jul;70(1):81-8.
3. i. Noar M, Mathias J, Kolatkar A. Gastrointestinal Myoelectrical Activity (GIMA) Biomarker for Noninvasive Diagnosis of Endometriosis. J Clin Med. 2024 May 13;13(10):2866. doi: 10.3390/jcm13102866. PMID: 38792407; PMCID: PMC11122642.
4. Zondervan, K.T.; Becker, C.M.; Koga, K.; Missmer, S.A.; Taylor, R.N.; Viganò, P. Endometriosis. Nat. Rev. Dis. Primers. 2018:4-9.
5. 1. Noar M, Mathias J, Kolatkar A. Validation of New GIMA Biomarker Signature of Endometriosis - Interim Data: Research Article. TechRxiv. August 26, 2024. DOI: 10.22541/au.172469630.08159498/v1
6. 1. Kitsantas P, Benson KN, Al-Farauki S, Knecht MK, Hennekens CH, et al. (2024) Emerging Diagnostic Tools for the Early Diagnosis of Endometriosis. J Reprod Med Gynecol Obstet 9: 171.
DISCLAIMER: THE ENDOSURE TEST IS A CLINICAL DECISION SUPPORT TOOL INTENDED TO INFORM AND ENHANCE A HEALTHCARE PROVIDER'S DECISION-MAKING PROCESS, WHICH MUST BE INDIVIDUALIZED FOR EACH PATIENT'S CIRCUMSTANCES AND TAKE INTO ACCOUNT THE FULL SCOPE OF MEDICAL DATA AND INFORMATION AVAILABLE TO THE PROVIDER. THE ENDOSURE TEST IS NOT INTENDED TO SUBSTITUTE, REPLACE, OVERRULE, OR DIRECT A HEALTHCARE PROVIDER’S JUDGMENT.
* US CUSTOMERS: Endosure is currently available for research use only and not clinical use.